[{"address1": "260 Sheridan Avenue", "address2": "Suite 400", "city": "Palo Alto", "state": "CA", "zip": "94306", "country": "United States", "phone": "650 800 6676", "website": "https://vincerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.", "fullTimeEmployees": 42, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ahmed M. Hamdy M.D.", "age": 58, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 657537, "exercisedValue": 0, "unexercisedValue": 12075}, {"maxAge": 1, "name": "Dr. Raquel E. Izumi Ph.D.", "age": 54, "title": "Co-Founder, President, COO, Secretary & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 591540, "exercisedValue": 0, "unexercisedValue": 12075}, {"maxAge": 1, "name": "Mr. Alexander A. Seelenberger M.B.A.", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 491694, "exercisedValue": 0, "unexercisedValue": 11278}, {"maxAge": 1, "name": "Mr. Tom C. Thomas J.D.", "age": 63, "title": "Founder, General Counsel & Chief Legal Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 444142, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John C. Byrd M.D.", "title": "Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans-Georg  Lerchen Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gabriela  Jairala", "title": "Vice President of Investor Relations & Corporate Communications and Chief of Staff", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Quarford M.B.A.", "title": "Vice President of Quality Operations & Compliance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Merrick SPHR", "title": "Senior Director of People & Culture and Head of Human Resource", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Beatrix  Stelte-Ludwig Ph.D.", "title": "Executive Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.185, "open": 0.1939, "dayLow": 0.1837, "dayHigh": 0.1998, "regularMarketPreviousClose": 0.185, "regularMarketOpen": 0.1939, "regularMarketDayLow": 0.1837, "regularMarketDayHigh": 0.1998, "forwardPE": -0.28507462, "volume": 692227, "regularMarketVolume": 692227, "averageVolume": 638334, "averageVolume10days": 868910, "averageDailyVolume10Day": 868910, "marketCap": 6427303, "fiftyTwoWeekLow": 0.183, "fiftyTwoWeekHigh": 9.372, "fiftyDayAverage": 0.33128, "twoHundredDayAverage": 1.3065, "currency": "USD", "enterpriseValue": -2037822, "floatShares": 26769893, "sharesOutstanding": 33650800, "sharesShort": 735417, "sharesShortPriorMonth": 813840, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.0219, "heldPercentInsiders": 0.15942, "heldPercentInstitutions": 0.24805, "shortRatio": 2.22, "shortPercentOfFloat": 0.0247, "impliedSharesOutstanding": 33650800, "bookValue": 0.425, "priceToBook": 0.44941175, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -26322000, "trailingEps": -0.86, "forwardEps": -0.67, "enterpriseToEbitda": 0.074, "52WeekChange": -0.6944, "SandP52WeekChange": 0.2764505, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VINC", "underlyingSymbol": "VINC", "shortName": "Vincerx Pharma, Inc.", "longName": "Vincerx Pharma, Inc.", "firstTradeDateEpochUtc": 1590586200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "46789548-9ff1-3829-9a39-73e43f85b2b7", "messageBoardId": "finmb_690173412", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.191, "targetHighPrice": 10.0, "targetLowPrice": 2.0, "targetMeanPrice": 6.0, "targetMedianPrice": 6.0, "recommendationKey": "none", "numberOfAnalystOpinions": 2, "totalCash": 10086000, "totalCashPerShare": 0.301, "ebitda": -27411000, "totalDebt": 1639000, "quickRatio": 2.055, "currentRatio": 2.166, "debtToEquity": 17.995, "returnOnAssets": -0.83273005, "returnOnEquity": -2.11856, "freeCashflow": -19563750, "operatingCashflow": -27965000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]